PFKFB3 and neoplasm: As standard chemotherapy inevitably leads to the development of chemoresistance, the observation that PFKFB3 inhibition therapy synergizes with carboplatin and paclitaxel in resistant cell lines of gynecological cancers to reduce tumor weight presents an intriguing therapeutic avenue [82].